Please wait while we load the requested 10-Q report or click the link below:
MIRAGEN THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES
|||MRG-110 advanced into clinical development with the initiation of two Phase 1 clinical trials in collaboration with Servier|
|||Preclinical data released in two separate ophthalmology programs targeting microRNA-29 and the microRNA-183/96/182 cluster|
|||Cobomarsen and MRG-201 to advance into Phase 2 clinical trials this year|
|||$78.1 million in cash and cash equivalents as of March 31, 2018 after completing a $37.9 million common stock offering in February 2018|
|||Conference call and webcast today at 4:30 p.m. ET|
BOULDER, CO, May 9, 2018 (GLOBE NEWSWIRE) miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today reported first quarter 2018 financial results and provided a corporate update.
With three product candidates now in clinical development and additional preclinical programs targeting multiple indications, we are continuing to advance, de-risk and build confidence in our pipeline of potential microRNA targeted therapies, said William S. Marshall, Ph.D., President and Chief Executive Officer of miRagen Therapeutics. Cobomarsen and MRG-201 remain on track to advance into Phase 2 clinical trials later this year, and we were pleased to have recently initiated two Phase 1 clinical trials for MRG-110 in collaboration with our partner, Servier. We also continued to expand the potential of our innovative microRNA technologies by unveiling a new preclinical program evaluating microRNA mimics of the microRNA-183/96/182 cluster involved in retinal degeneration.
Marshall continued, We are encouraged by the advancement of our pipeline of microRNA therapeutic candidates and excited about the opportunities that our microRNA focused discovery and development platform could provide as our clinical programs continue to show promising efficacy and safety profiles.
Recent Achievements and Anticipated Progress
|||miRagen closed enrollment in its Phase 1 cutaneous T-cell lymphoma (CTCL) trial and plans to release additional data from this study, including response rates from longer-term duration of treatment, in the first half of 2018.|
|||miRagen continued to evaluate patients in its Phase 1 clinical trial of cobomarsen for other oncology indications and plans to release interim Phase 1 data in at least one of these potential expansion indications in the second half of 2018.|
The following information was filed by Miragen Therapeutics, Inc. (MGEN) on Wednesday, May 9, 2018 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one quarter to another to evaluate Miragen Therapeutics, Inc.'s financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Miragen Therapeutics, Inc..